Aptevo Therapeutics (APVO) Competitors $0.96 -0.08 (-7.69%) Closing price 04:00 PM EasternExtended Trading$0.94 -0.02 (-2.50%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. NKGN, CARM, OBSV, PMCB, KPRX, AIMD, SNSE, ADXN, BCLI, and ACXPShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include NKGen Biotech (NKGN), Carisma Therapeutics (CARM), ObsEva (OBSV), PharmaCyte Biotech (PMCB), Kiora Pharmaceuticals (KPRX), Ainos (AIMD), Sensei Biotherapeutics (SNSE), Addex Therapeutics (ADXN), Brainstorm Cell Therapeutics (BCLI), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. NKGen Biotech Carisma Therapeutics ObsEva PharmaCyte Biotech Kiora Pharmaceuticals Ainos Sensei Biotherapeutics Addex Therapeutics Brainstorm Cell Therapeutics Acurx Pharmaceuticals NKGen Biotech (NYSE:NKGN) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment. Which has more risk and volatility, NKGN or APVO? NKGen Biotech has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.75, suggesting that its stock price is 475% more volatile than the S&P 500. Is NKGN or APVO more profitable? NKGen Biotech's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Aptevo Therapeutics N/A -488.93%-152.51% Do analysts prefer NKGN or APVO? Aptevo Therapeutics has a consensus target price of $10,952.00, suggesting a potential upside of 1,140,733.33%. Given Aptevo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aptevo Therapeutics is more favorable than NKGen Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in NKGN or APVO? 76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer NKGN or APVO? In the previous week, NKGen Biotech and NKGen Biotech both had 2 articles in the media. Aptevo Therapeutics' average media sentiment score of 0.43 beat NKGen Biotech's score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment NKGen Biotech Neutral Aptevo Therapeutics Neutral Which has preferable valuation & earnings, NKGN or APVO? Aptevo Therapeutics has higher revenue and earnings than NKGen Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen Biotech$80K73.15-$82.94M-$2.45-0.05Aptevo Therapeutics$3.11M0.45-$24.13MN/AN/A Does the MarketBeat Community favor NKGN or APVO? Aptevo Therapeutics received 199 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformNKGen BiotechN/AN/AAptevo TherapeuticsOutperform Votes19950.00% Underperform Votes19950.00% SummaryAptevo Therapeutics beats NKGen Biotech on 9 of the 13 factors compared between the two stocks. Remove Ads Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E RatioN/A6.7921.7317.81Price / Sales0.45225.93379.1494.58Price / CashN/A65.6738.1534.64Price / Book0.295.866.464.00Net Income-$24.13M$141.86M$3.20B$247.23M7 Day Performance-4.95%8.98%6.54%7.26%1 Month Performance-60.17%-12.65%-8.55%-6.26%1 Year Performance-99.91%-11.99%10.33%-0.18% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.2062 of 5 stars$0.96-7.7%$10,952.00+1,140,733.3%-99.9%$1.40M$3.11M0.0050Short Interest ↑NKGNNKGen BiotechN/A$0.13-27.8%N/A-90.0%$8.09M$80,000.00-0.03N/ANews CoverageCARMCarisma Therapeutics2.4767 of 5 stars$0.19+0.7%$2.74+1,319.7%-88.9%$8.07M$19.63M-0.1220Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150PMCBPharmaCyte Biotech2.4406 of 5 stars$1.14-8.1%N/A-46.2%$7.83MN/A2.154Short Interest ↓Positive NewsGap DownKPRXKiora Pharmaceuticals3.9445 of 5 stars$2.60-1.1%$10.00+284.6%-46.6%$7.80M$16M2.5010Short Interest ↓AIMDAinos0.9137 of 5 stars$0.50-5.2%N/A-45.5%$7.68M$20,729.00-0.3040Short Interest ↓News CoverageGap DownSNSESensei Biotherapeutics4.1238 of 5 stars$0.30+3.9%$4.25+1,316.7%-63.4%$7.56MN/A-0.2540Short Interest ↑ADXNAddex Therapeutics1.8893 of 5 stars$7.08-4.8%$30.00+324.0%-72.7%$7.50M$556,045.00-20.8130Short Interest ↑Gap DownBCLIBrainstorm Cell Therapeutics3.6827 of 5 stars$1.12-2.6%$30.00+2,578.6%-91.1%$7.31MN/A-0.2340Gap UpACXPAcurx Pharmaceuticals2.2607 of 5 stars$0.33+2.6%$12.00+3,556.3%-78.4%$7.24MN/A-0.303 Remove Ads Related Companies and Tools Related Companies NKGN Alternatives CARM Alternatives OBSV Alternatives PMCB Alternatives KPRX Alternatives AIMD Alternatives SNSE Alternatives ADXN Alternatives BCLI Alternatives ACXP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APVO Stock Free APVO Stock Alerts